Literature DB >> 6610499

Inadequate immunity to measles in children vaccinated at an early age: effect of revaccination.

F L Black, L L Berman, M Libel, C A Reichelt, F D Pinheiro, A Travassos da Rosa, F Figueira, E Siqueira Gonzales.   

Abstract

This report describes a follow-up serological study of 79 Brazilian children who, because of their young age, had failed to develop protective levels of immunity after vaccination against measles. There was serological evidence that infection with wild virus had occurred at a rate of about 17% per annum. Approximately 1(1/2) years after the initial vaccination, 46% of the uninfected children maintained very low levels of neutralizing antibody, but did not have a measurable haemagglutination-inhibition titre. Revaccination did not elicit an IgM response in most children, but stimulated anti-measles IgG production in all of them. In 36% of the children, the IgG titres fell again within three months to levels that may permit reinfection. If it is assumed that some of the persistent titres can be attributed to wild virus infection, the actual effect of revaccination would have been to immunize no more than 60% of the susceptible group. The results suggest that early administration of measles vaccine may produce a cohort of children with inadequate immunity who cannot be fully immunized by revaccination. The implications of these findings for measles immunization programmes are discussed.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6610499      PMCID: PMC2536301     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  17 in total

1.  Booster vaccination with further live attenuated measles vaccine.

Authors:  J W Bass; S B Halstead; G W Fischer; J K Podgore; W R Pearl; M Schydlower; R A Wiebe; F M Ching
Journal:  JAMA       Date:  1976-01-05       Impact factor: 56.272

2.  Measles immunity: reimmunization of children who previously received live measles vaccine and gamma globulin.

Authors:  A M Arbeter; J H Arthur; G J Blakeman; K McIntosh
Journal:  J Pediatr       Date:  1972-10       Impact factor: 4.406

3.  A clinical and serologic study of 103 children with measles vaccine failure.

Authors:  J D Cherry; R D Feigin; P G Shackelford; D R Hinthorn; R R Schmidt
Journal:  J Pediatr       Date:  1973-05       Impact factor: 4.406

4.  Measles IgM response during reinfection of previously vaccinated children.

Authors:  C C Linnemann; M E Hegg; T C Rotte; J P Phair; G M Schiff
Journal:  J Pediatr       Date:  1973-05       Impact factor: 4.406

5.  Urban measles in the vaccine era: a clinical, epidemiologic, and serologic study.

Authors:  J D Cherry; R D Feigin; L A Lobes; D R Hinthorn; P G Shackelford; R H Shirley; R D Lins; S C Choi
Journal:  J Pediatr       Date:  1972-08       Impact factor: 4.406

6.  Clinical epidemiology of sporadic measles in a highly immunized population.

Authors:  W Schaffner; A E Schluederberg; E B Byrne
Journal:  N Engl J Med       Date:  1968-10-10       Impact factor: 91.245

7.  Epidemic measles in a highly vaccinated population.

Authors:  D M Shasby; T C Shope; H Downs; K L Herrmann; J Polkowski
Journal:  N Engl J Med       Date:  1977-03-17       Impact factor: 91.245

8.  Measles revaccination. Persistence and degree of antibody titer by type of immune response.

Authors:  J Deseda-Tous; J D Cherry; M J Spencer; R C Welliver; K M Boyer; J P Dudley; J M Zahradnik; P J Krause; E W Walbergh
Journal:  Am J Dis Child       Date:  1978-03

9.  Studies on further attenuated liver measles vaccine. VII. Development and evaluation of CAM-70 measles virus vaccine.

Authors:  Y Okuno; S Ueda; T Kurimura; N Suzuki; K Yamanishi
Journal:  Biken J       Date:  1971-09

10.  Additional evidence against measles vaccine administration to infants less than 12 months of age: altered immune response following active/passive immunization.

Authors:  J Wilkins; P F Wehrle
Journal:  J Pediatr       Date:  1979-06       Impact factor: 4.406

View more
  8 in total

1.  Measles immunisation in developing countries.

Authors:  S K Obaro
Journal:  BMJ       Date:  1994-02-05

2.  Evaluation of the measles, mumps and rubella immunisation programme in Spain by using a sero-epidemiological survey.

Authors:  C Amela; I Pachón; F de Ory
Journal:  Eur J Epidemiol       Date:  2003       Impact factor: 8.082

3.  Duration of immunity following immunization with live measles vaccine: 15 years of observation in Zhejiang Province, China.

Authors:  B Dai; Z H Chen; Q C Liu; T Wu; C Y Guo; X Z Wang; H H Fang; Y Z Xiang
Journal:  Bull World Health Organ       Date:  1991       Impact factor: 9.408

4.  Comparison of AIK-C measles vaccine in infants at 6 months with Schwarz vaccine at 9 months: a randomized controlled trial in Ghana.

Authors:  F K Nkrumah; M Osei-Kwasi; S K Dunyo; K A Koram; E A Afari
Journal:  Bull World Health Organ       Date:  1998       Impact factor: 9.408

5.  Reduced childhood mortality after standard measles vaccination at 4-8 months compared with 9-11 months of age.

Authors:  P Aaby; M Andersen; M Sodemann; M Jakobsen; J Gomes; M Fernandes
Journal:  BMJ       Date:  1993-11-20

6.  Lack of efficacy of the standard potency Edmonston-Zagreb live, attenuated measles vaccine in African infants.

Authors:  P Kiepiela; H M Coovadia; W E Loening; P Coward; G Botha; J Hugo; P J Becker
Journal:  Bull World Health Organ       Date:  1991       Impact factor: 9.408

7.  Identification of primary and secondary measles vaccine failures by measurement of immunoglobulin G avidity in measles cases during the 1997 São Paulo epidemic.

Authors:  Cláudio S Pannuti; Ricardo José Morello; José Cássio de Moraes; Suely Pires Curti; Ana Maria S Afonso; Maria Cláudia Corrêa Camargo; Vanda A U F de Souza
Journal:  Clin Diagn Lab Immunol       Date:  2004-01

8.  Seroprevalence of antibodies to measles, mumps, and rubella among Thai population: evaluation of measles/MMR immunization programme.

Authors:  Piyanit Tharmaphornpilas; Pornsak Yoocharean; Aim-Orn Rasdjarmrearnsook; Apiradee Theamboonlers; Yong Poovorawan
Journal:  J Health Popul Nutr       Date:  2009-02       Impact factor: 2.000

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.